Unjoni Ewropea - Malti - EMA (European Medicines Agency)

krka, d.d., novo mesto - sildenafil - disfunzjoni erettili - uroloġiċi - trattament ta 'rġiel b'funzjoni ta' disfunzjoni erettili, li hija l-inkapaċità li tikseb jew iżżomm erezzjoni tal-pene suffiċjenti għal prestazzjoni sesswali sodisfaċenti. sabiex jinħassu milli kieku jittieħed biex ikun effettiv, hija meħtieġa stimulazzjoni sesswali.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

mediwound germany gmbh - proteolytic enzymes enriched in bromelain - debridament - preparazzjonijiet għat-trattament ta 'feriti u ulċeri - nexobrid huwa indikat għat-tneħħija ta 'eschar f'adulti b'ħruq termali parzjali u ta' ħxuna sħiħa.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

roche registration gmbh - pertuzumab, trastuzumab - neoplażmi tas-sider - aġenti antineoplastiċi - early breast cancer (ebc)phesgo is indicated for use in combination with chemotherapy in:the neoadjuvant treatment of adult patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrencethe adjuvant treatment of adult patients with her2-positive early breast cancer at high risk of recurrencemetastatic breast cancer (mbc)phesgo is indicated for use in combination with docetaxel in adult patients with her2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-her2 therapy or chemotherapy for their metastatic disease.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

novartis europharm ltd - aliskiren, amlodipine - pressjoni għolja - aġenti li jaġixxu fuq is-sistema renin-angiotensin - rasilamlo huwa indikat għat-trattament ta 'pressjoni għolja essenzjali f'pazjenti adulti li l-pressjoni tad-demm tagħhom mhix ikkontrollata b'mod adegwat b'aliskiren jew amlodipine użat waħdu.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

gilead sciences ireland uc - bulevirtide acetate - hepatitis d, chronic - antivirali għal użu sistemiku - hepcludex is indicated for the treatment of chronic hepatitis delta virus (hdv) infection in plasma (or serum) hdv-rna positive adult patients with compensated liver disease.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

daiichi sankyo europe gmbh - trastuzumab deruxtecan - neoplażmi tas-sider - aġenti antineoplastiċi - breast cancerher2-positive breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-positive breast cancer who have received one or more prior anti-her2-based regimens. her2-low breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4. non-small cell lung cancer (nsclc)enhertu as monotherapy is indicated for the treatment of adult patients with advanced nsclc whose tumours have an activating her2 (erbb2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. gastric cancerenhertu as monotherapy is indicated for the treatment of adult patients with advanced her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma who have received a prior trastuzumab-based regimen.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - ombitasvir, paritaprevir, ritonavir - epatite Ċ, kronika - antivirali għal użu sistemiku - viekirax huwa indikat flimkien ma 'prodotti mediċinali oħra għall-kura ta' l-epatite Ċ kronika (chc) fl-adulti. għall-vajrus tal-epatite Ċ (hcv) ġenotip attività speċifika.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

astrazeneca ab - sodium żirkonju cyclosilicate - iperkalemija - il-prodotti terapewtiċi l-oħra kollha - lokelma huwa indikat għall-kura ta ' l-iperkalemija f'pazjenti adulti.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

roche registration gmbh - vismodegib - karċinoma, Ċellula basal - aġenti antineoplastiċi - erivedge huwa indikat għall-kura ta ' pazjenti adulti bil -: - sintomatika metastatiku tal-karċinoma taċ-ċellola bażali - lokalment avvanzat karċinoma taċ-ċellola bażali inadegwata għall-kirurġija jew radjoterapija.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

sanofi winthrop industrie - cabazitaxel - neoplasmi prostatiċi - aġenti antineoplastiċi - jevtana flimkien ma 'prednisone jew prednisolone huwa indikat għall-kura ta' pazjenti b'kanċer metastatiku tal-prostata refrattorju ormonali li qabel kien ikkurat b'regimen li fih docetaxel.